Jerusalem based Oramed Pharmaceuticals Inc. (Nasdaq:ORMP), which develops orally administered drugs as a substitute for injections, has announced that the Israel Securities Authority has authorized the dual listing of its shares on the Tel Aviv Stock Exchange (TASE), in addition to Nasdaq.

For more information, see:

http://www.globes.co.il/en/article-oramed-to-dual-list-on-tase-1001195976